Phioanh Leia Nghiemphu

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Safety of anticoagulation use and bevacizumab in patients with glioma
    Phioanh Leia Nghiemphu
    Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, RNRC 1 230, Los Angeles, CA 90095, USA
    Neuro Oncol 10:355-60. 2008
  2. pmc Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience
    P L Nghiemphu
    Department of Neurology, Jonsson Comprehensive Cancer Center, University of California at Los Angeles and David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Neurology 72:1217-22. 2009
  3. pmc A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma
    Phioanh Leia Nghiemphu
    University of California, Los Angeles, CA 90095, USA
    Int J Radiat Oncol Biol Phys 81:1422-7. 2011
  4. pmc A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
    Phioanh Leia Nghiemphu
    Department of Neurology, University of California, Los Angeles, CA 90230, USA
    J Neurooncol 110:245-50. 2012
  5. doi request reprint Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability
    Albert Lai
    Department of Neurology, David Geffen School of Medicine at University of California Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA
    Int J Radiat Oncol Biol Phys 71:1372-80. 2008
  6. pmc The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity
    Maya Remington
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Neuro Oncol 11:22-32. 2009
  7. pmc Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    Igor Vivanco
    Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:458-71. 2012
  8. pmc Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
    Albert Lai
    David Geffen School of Medicine at theUniversity of California at Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 29:4482-90. 2011

Collaborators

Detail Information

Publications8

  1. pmc Safety of anticoagulation use and bevacizumab in patients with glioma
    Phioanh Leia Nghiemphu
    Department of Neurology, David Geffen School of Medicine at UCLA, 710 Westwood Plaza, RNRC 1 230, Los Angeles, CA 90095, USA
    Neuro Oncol 10:355-60. 2008
    ..In this retrospective review, anticoagulation did not lead to any major hemorrhages and does not appear to be a contraindication for starting bevacizumab therapy...
  2. pmc Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience
    P L Nghiemphu
    Department of Neurology, Jonsson Comprehensive Cancer Center, University of California at Los Angeles and David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Neurology 72:1217-22. 2009
    ..Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared with historic controls but not in randomized trials...
  3. pmc A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma
    Phioanh Leia Nghiemphu
    University of California, Los Angeles, CA 90095, USA
    Int J Radiat Oncol Biol Phys 81:1422-7. 2011
    ....
  4. pmc A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
    Phioanh Leia Nghiemphu
    Department of Neurology, University of California, Los Angeles, CA 90230, USA
    J Neurooncol 110:245-50. 2012
    ..The combination of erlotinib and sirolimus is difficult to tolerate at dosages higher than previously reported in phase II trials...
  5. doi request reprint Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability
    Albert Lai
    Department of Neurology, David Geffen School of Medicine at University of California Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA
    Int J Radiat Oncol Biol Phys 71:1372-80. 2008
    ....
  6. pmc The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity
    Maya Remington
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Neuro Oncol 11:22-32. 2009
    ..These findings may provide a clue to determining the clinical significance of MGMT coding-region polymorphisms...
  7. pmc Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    Igor Vivanco
    Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Discov 2:458-71. 2012
    ....
  8. pmc Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
    Albert Lai
    David Geffen School of Medicine at theUniversity of California at Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 29:4482-90. 2011
    ..To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1(R132) mutation status...